PGE1 en es it fr

PGE1 Brand names, PGE1 Analogs

PGE1 Brand Names Mixture

  • No information avaliable

PGE1 Chemical_Formula


PGE1 RX_link

PGE1 fda sheet


PGE1 msds (material safety sheet)


PGE1 Synthesis Reference

No information avaliable

PGE1 Molecular Weight

354.481 g/mol

PGE1 Melting Point

115 - 116 oC

PGE1 H2O Solubility

26.7 mg/L

PGE1 State




PGE1 Dosage Forms

Liquid; Powder for solution; Solution; Suppository

PGE1 Indication

For palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Also for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.

PGE1 Pharmacology

Alprostadil (prostaglandin E1) is produced endogenously to relax vascular smooth muscle and cause vasodilation. In adult males, the vasodilatory effects of alprostadil on the cavernosal arteries and the trabecular smooth muscle of the corpora cavernosa result in rapid arteriolar inflow and expansion of the lacunar spaces within the corpora. As the expanded corporal sinusoids are compressed against the tunica albuginea, venous outflow through the subtunical vessels is impeded and penile rigidity develops. This is referred to as the corporal veno-occlusive mechanism. In infants, the vasodilatory effects of alprostadil increase pulmonary or systemic blood flow.

PGE1 Absorption

The absolute bioavailability of alprostadil has not been determined.

PGE1 side effects and Toxicity

Oral, mouse: LD50 = 186 mg/kg; Oral, rat: LD50 = 228 mg/kg. Apnea, bradycardia, pyrexia, hypotension, and flushing may be signs of drug overdosage.

PGE1 Patient Information

PGE1 Organisms Affected

Humans and other mammals